Home / Latin America and the Caribbean / GUY

Guyana

Guyana appears only through international and donor bodies that compile figures across many countries, and no figures for the country are read directly from a national publisher. The assessment of national sources, country by country, is set out on the Methods page.

11,000

People living with HIV, 2025

WHO Global Health Observatory

69.0%

On antiretroviral treatment, 2025

WHO Global Health Observatory

$74

United States HIV disbursements, 2024

OECD Creditor Reporting System

$883k

External HIV financing, all donors, 2024

OECD Creditor Reporting System

External HIV financing

OECD CRS · ForeignAssistance.gov

All donors
United States, OECD record
The Global Fund
United States, self-reported

Year	All donors	United States, OECD record	The Global Fund	United States, self-reported
2001	—	—	—	$11k
2002	$1.5m	$1.4m	—	$49k
2003	$3.6m	$3.5m	—	$3.0m
2004	$7.3m	$7.3m	—	$4.1m
2005	$12.3m	$9.7m	$2.1m	$10.0m
2006	$21.3m	$17.9m	$2.5m	$15.6m
2007	$20.1m	$17.0m	$1.6m	$15.7m
2008	$28.3m	$20.1m	$6.5m	$23.2m
2009	$25.5m	$17.0m	$5.8m	$17.3m
2010	$20.0m	$15.5m	$3.5m	$15.9m
2011	$18.0m	$11.2m	$6.0m	$10.2m
2012	$12.7m	$11.3m	$764k	$10.9m
2013	$10.2m	$7.4m	$2.2m	$9.3m
2014	$8.7m	$6.5m	$2.0m	$7.1m
2015	$5.9m	$3.2m	$2.1m	$3.5m
2016	$5.9m	$3.1m	$1.9m	$3.3m
2017	$5.5m	$3.0m	$1.8m	$3.0m
2018	$3.0m	$2.2m	$749k	$2.4m
2019	$2.3m	$1.5m	$817k	$562k
2020	$805k	$279k	$522k	$649k
2021	$1.8m	$1.3m	$532k	$1.2m
2022	$1.9m	$1.2m	$677k	$840k
2023	$1.2m	$241k	$903k	$354k
2024	$883k	$74	$883k	$-1k

24 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Disbursements reported for the country. The OECD record and the United States self-reported record are drawn separately. The two records cover the same United States disbursements, but the OECD record is filed by calendar year and the self-reported record by United States fiscal year.

People living with HIV and people on treatment

UNAIDS AIDSinfo

People living with HIV
People on treatment

Year	People living with HIV	People living with HIV (lower)	People living with HIV (upper)	People on treatment
2000	4,100	2,900	6,000	—
2001	4,400	3,200	6,500	—
2002	4,700	3,500	6,900	—
2003	4,900	3,700	7,400	—
2004	5,200	3,800	7,700	—
2005	5,400	4,000	8,100	—
2006	5,700	4,300	8,500	—
2007	6,000	4,500	8,900	—
2008	6,200	4,600	9,300	—
2009	6,400	4,700	9,800	—
2010	6,600	4,800	10,000	3,100
2011	6,800	4,900	10,000	3,400
2012	7,100	5,100	11,000	3,700
2013	7,300	5,200	11,000	4,100
2014	7,500	5,400	12,000	4,300
2015	7,800	5,600	12,000	4,500
2016	8,000	5,700	12,000	4,900
2017	8,200	5,900	12,000	5,200
2018	8,900	6,400	13,000	5,600
2019	9,000	6,500	13,000	6,000
2020	9,300	6,700	14,000	5,900
2021	9,600	7,000	14,000	6,100
2022	9,900	7,300	14,000	6,400
2023	10,000	7,500	15,000	6,800
2024	11,000	7,700	15,000	7,300

25 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Modelled estimates. The shaded area is the published uncertainty interval around the number of people living with HIV, because a single estimate without the interval would overstate the precision of the model.

The treatment cascade

UNAIDS AIDSinfo

Diagnosed
On treatment
Virally suppressed

Year	Diagnosed	On treatment	Virally suppressed
2010	—	46.0%	—
2011	—	50.0%	—
2012	—	53.0%	—
2013	—	56.0%	—
2014	—	57.0%	—
2015	72.0%	58.0%	—
2016	81.0%	61.0%	50.0%
2017	86.0%	64.0%	52.0%
2018	85.0%	62.0%	54.0%
2019	90.0%	66.0%	57.0%
2020	91.0%	63.0%	55.0%
2021	93.0%	64.0%	—
2022	93.0%	65.0%	—
2023	92.0%	66.0%	58.0%
2024	92.0%	69.0%	65.0%

15 rows, as drawn above. Values are rounded for display, and the download gives the unrounded values.

Every line is a percentage of all people living with HIV, so the three lines share a denominator and can be compared directly. Viral suppression in the figure is the share of all people living with HIV who are virally suppressed, and not the narrower third 95 target, which counts only people on treatment.

Data-quality flags on Guyana

HIV tests performed with the result returned to the person, 2022 (PEPFAR Panorama Spotlight). The value moved from 1,015 in 2021 to 4,009 in 2022, a change of more than threefold in a single year. The move from 1,015 to 4,009 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2021 and 2022 are not comparable. Check the figures by reporting organisation before reading a trend across 2021 and 2022.

Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS), 2022 (PEPFAR Panorama Spotlight). The value moved from 14 in 2021 to 86 in 2022, a change of more than threefold in a single year. The move from 14 to 86 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2021 and 2022 are not comparable. Check the figures by reporting organisation before reading a trend across 2021 and 2022.

Sources of the figures for Guyana

3,260 rows

Source	Type	Rows	Indicators	Years	Read from	Retrieved
UNICEF HIV/AIDS dataset	Modelled estimate	1,376	5	2010–2025	sdmx.data.unicef.org	2026-10-20
UNAIDS AIDSinfo	Modelled estimate	804	29	2000–2024	aidsinfo.unaids.org	2026-10-20
WHO Global Health Observatory	Modelled estimate	264	12	2000–2025	ghoapi.azureedge.net	2026-10-12
WHO Global Tuberculosis Programme	Programme record	185	17	2000–2025	extranet.who.int	2026-10-16
ForeignAssistance.gov	Expenditure account	100	5	2001–2024	foreignassistance.gov	2026-10-29
Global Fund Data Service	Programme record	93	11	2017–2025	fetch.theglobalfund.org	2026-10-12
Demographic and Health Surveys	Survey	76	3	2005–2009	api.dhsprogram.com	2026-10-16
OECD Creditor Reporting System	Expenditure account	66	3	2002–2024	sdmx.oecd.org	2026-10-12
World Bank Open Data	Modelled estimate	51	2	2000–2025	api.worldbank.org	2026-10-12
IATI, through d-portal	Expenditure account	48	3	2005–2026	d-portal.org	2026-10-12
PAHO Core Indicators	Programme record	42	1	2012–2025	opendata.paho.org	2026-10-13
WHO HIV testing services dashboard	Programme record	33	5	2018–2024	eic-database-290813.ew.r.appspot.com	2026-10-14
WHO Global Health Expenditure Database	Expenditure account	28	7	2016–2019	apps.who.int	2026-10-12
PEPFAR testing by modality	Programme record	26	6	2018–2022	data.pepfar.gov	2026-10-12
PEPFAR Panorama Spotlight	Programme record	19	5	2018–2022	data.pepfar.gov	2026-10-12
PEPFAR results by funding agency	Programme record	14	4	2018–2022	data.pepfar.gov	2026-10-12
PEPFAR budgets and expenditure	Expenditure account	13	6	2021–2023	data.pepfar.gov	2026-10-12
PEPFAR operating-unit budgets	Expenditure account	9	2	2010–2020	data.pepfar.gov	2026-10-12
PAHO Interactive HIV Data Dashboard	Programme record	6	1	2020–2025	paho.org	2026-10-14
PEPFAR commodity procurement plans	Expenditure account	4	4	2021	data.pepfar.gov	2026-10-12
Global Fund allocations	Expenditure account	3	1	2017–2023	fetch.theglobalfund.org	2026-10-12

Indicators held

93 of 150

Indicator	Domain	Unit	Rows	Years	Sources	Most recent value
Actual expenditure on collaborative TB/HIV activities	Financing	USD	8	2017–2024	WHO Global Tuberculosis Programme	$33k (2024)
Budget required for collaborative TB/HIV activities	Financing	USD	8	2018–2025	WHO Global Tuberculosis Programme	$24k (2025)
Country-reported HIV expenditure, all sources	Financing	USD	1	2012	UNAIDS AIDSinfo	$21.9m (2012)
Domestic funding received by the national TB programme	Financing	USD	8	2017–2024	WHO Global Tuberculosis Programme	$903k (2024)
Expected Global Fund funding for the national TB programme	Financing	USD	8	2018–2025	WHO Global Tuberculosis Programme	$428k (2025)
Expected USAID funding for the national TB programme	Financing	USD	7	2018–2025	WHO Global Tuberculosis Programme	$0 (2025)
Expected domestic funding for the national TB programme	Financing	USD	8	2018–2025	WHO Global Tuberculosis Programme	$863k (2025)
Expected funding for collaborative TB/HIV activities	Financing	USD	8	2018–2025	WHO Global Tuberculosis Programme	$33k (2025)
External HIV and STD spending, national health accounts	Financing	USD	4	2016–2019	WHO Global Health Expenditure Database	$4.0m (2019)
External HIV financing (all donors, ODA)	Financing	USD	23	2002–2024	OECD Creditor Reporting System	$883k (2024)
External HIV financing from governments other than the United States (IATI)	Financing	USD	12	2009–2025	IATI, through d-portal	$0 (2025)
External HIV financing from multilateral bodies other than the Global Fund (IATI)	Financing	USD	14	2012–2026	IATI, through d-portal	$45k (2026)
External HIV financing from the United States (ODA)	Financing	USD	47	2001–2024	ForeignAssistance.gov, OECD Creditor Reporting System	$74 (2024)
Funding received for collaborative TB/HIV activities	Financing	USD	8	2017–2024	WHO Global Tuberculosis Programme	$33k (2024)
Global Fund HIV allocation for a whole three-year cycle, not an annual figure	Financing	USD per three-year allocation cycle	3	2017–2023	Global Fund allocations	4,066,316 (2023)
Global Fund HIV disbursements to the country	Financing	USD	42	2005–2026	IATI, through d-portal, OECD Creditor Reporting System	$1.8m (2026)
Global Fund funding received by the national TB programme	Financing	USD	8	2017–2024	WHO Global Tuberculosis Programme	$428k (2024)
Government HIV and STD spending as a share of government health spending	Financing	percent	4	2016–2019	WHO Global Health Expenditure Database	6.0% (2019)
Government HIV and STD spending, national health accounts	Financing	USD	4	2016–2019	WHO Global Health Expenditure Database	$9.0m (2019)
HIV and STD spending as a share of all external health spending	Financing	percent	4	2016–2019	WHO Global Health Expenditure Database	58.9% (2019)
HIV and STD spending as a share of all health spending	Financing	percent	4	2016–2019	WHO Global Health Expenditure Database	5.7% (2019)
HIV and STD spending, national health accounts	Financing	USD	4	2016–2019	WHO Global Health Expenditure Database	$14.5m (2019)
PEPFAR expenditure, HHS/CDC	Financing	USD	3	2021–2023	PEPFAR budgets and expenditure	$276k (2023)
PEPFAR expenditure, USAID	Financing	USD	2	2021–2022	PEPFAR budgets and expenditure	$384k (2022)
PEPFAR expenditure, all US agencies	Financing	USD	4	2020–2023	PEPFAR budgets and expenditure, PEPFAR operating-unit budgets	$276k (2023)
PEPFAR planned commodity procurement, like for like	Financing	USD	1	2021	PEPFAR commodity procurement plans	$79k (2021)
PEPFAR planned funding (budget), all US agencies	Financing	USD	10	2010–2022	PEPFAR budgets and expenditure, PEPFAR operating-unit budgets	$439k (2022)
PEPFAR planned funding, HHS/CDC	Financing	USD	1	2021	PEPFAR budgets and expenditure	$394k (2021)
PEPFAR planned funding, USAID	Financing	USD	2	2021–2022	PEPFAR budgets and expenditure	$439k (2022)
PEPFAR planned procurement of antiretroviral drugs	Financing	USD	1	2021	PEPFAR commodity procurement plans	$0 (2021)
PEPFAR planned procurement of laboratory commodities	Financing	USD	1	2021	PEPFAR commodity procurement plans	$62k (2021)
PEPFAR planned procurement of rapid test kits	Financing	USD	1	2021	PEPFAR commodity procurement plans	$16k (2021)
Private HIV and STD spending, national health accounts	Financing	USD	4	2016–2019	WHO Global Health Expenditure Database	$1.5m (2019)
US HIV disbursements managed by Health and Human Services	Financing	USD	22	2003–2024	ForeignAssistance.gov	$0 (2024)
US HIV disbursements managed by USAID	Financing	USD	24	2001–2024	ForeignAssistance.gov	$-1k (2024)
US HIV disbursements managed by other US agencies	Financing	USD	18	2004–2021	ForeignAssistance.gov	$0 (2021)
US HIV disbursements managed by the State Department	Financing	USD	12	2008–2019	ForeignAssistance.gov	$0 (2019)
USAID funding received by the national TB programme	Financing	USD	7	2017–2024	WHO Global Tuberculosis Programme	$0 (2024)
% of ALL PLHIV who are virally suppressed	Treatment cascade	percent	15	2016–2025	UNAIDS AIDSinfo, WHO Global Health Observatory	60.0% (2025)
% of PLHIV on ART (second 95, PLHIV base)	Treatment cascade	percent	68	2000–2025	UNAIDS AIDSinfo, WHO Global Health Observatory	69.0% (2025)
% of PLHIV who have been diagnosed (first 95)	Treatment cascade	percent	20	2015–2025	UNAIDS AIDSinfo, WHO Global Health Observatory	93.0% (2025)
% of estimated HIV-positive incident TB cases on TB treatment and ART	Treatment cascade	percent	20	2003–2024	UNAIDS AIDSinfo	41.9% (2024)
% of people currently enrolled in HIV treatment started on TB preventive therapy	Treatment cascade	percent	4	2019–2023	UNAIDS AIDSinfo	7.0% (2023)
% of people living with HIV on ART who completed a course of TB preventive therapy	Treatment cascade	percent	1	2022	UNAIDS AIDSinfo	85.1% (2022)
% of people newly enrolled in HIV treatment diagnosed with TB disease	Treatment cascade	percent	9	2014–2023	UNAIDS AIDSinfo	10.5% (2023)
% of people newly enrolled in HIV treatment started on TB preventive therapy	Treatment cascade	percent	9	2013–2023	UNAIDS AIDSinfo	63.7% (2023)
% of people on ART who are virally suppressed (third 95)	Treatment cascade	percent	8	2016–2025	WHO Global Health Observatory	87.0% (2025)
% of returned HIV test results that were positive	Treatment cascade	percent	29	2018–2024	UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard	0.8% (2024)
HIV self-test kits distributed	Treatment cascade	count	3	2022–2024	WHO HIV testing services dashboard	10,489 (2024)
HIV tests performed at a health facility	Treatment cascade	count	5	2018–2020	PEPFAR testing by modality, WHO HIV testing services dashboard	2,794 (2020)
HIV tests performed through community outreach	Treatment cascade	count	7	2018–2022	PEPFAR testing by modality, WHO HIV testing services dashboard	4,009 (2022)
HIV tests performed with the result returned to the person	Treatment cascade	count	47	2017–2024	Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard	88,939 (2024)
HIV-exposed infants tested within two months of birth	Treatment cascade	percent	14	2010–2024	UNAIDS AIDSinfo	43.0% (2024)
HIV-positive TB patients given co-trimoxazole preventive therapy	Treatment cascade	count	1	2018	Global Fund Data Service	95 (2018)
HIV-positive TB patients started or continued on ART	Treatment cascade	count	24	2015–2025	Global Fund Data Service, WHO Global Tuberculosis Programme	38 (2025)
Key-population people tested for HIV (count over the period)	Treatment cascade	count	25	2017–2025	Global Fund Data Service	By population group, sex or age only, to 2025
New HIV diagnoses with a CD4 count below 200	Treatment cascade	percent	3	2016–2019	UNAIDS AIDSinfo	18.0% (2019)
Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS)	Treatment cascade	count	3	2018–2020	PEPFAR results by funding agency	41 (2020)
Newly diagnosed at USAID-funded partners (MER HTS_TST_POS)	Treatment cascade	count	5	2018–2022	PEPFAR results by funding agency	86 (2022)
Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW)	Treatment cascade	count	3	2018–2020	PEPFAR results by funding agency	260 (2020)
Notified HIV cases, national case surveillance	Treatment cascade	count	42	2012–2025	PAHO Core Indicators	528 (2025)
Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS)	Treatment cascade	count	10	2018–2022	PEPFAR Panorama Spotlight, PEPFAR testing by modality	86 (2022)
Number of PLHIV virally suppressed (VL<1000)	Treatment cascade	count	3	2018–2020	PEPFAR Panorama Spotlight	1,609 (2020)
Number of people on ART (PEPFAR MER TX_CURR)	Treatment cascade	count	82	2000–2025	Global Fund Data Service, PEPFAR Panorama Spotlight, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO Global Tuberculosis Programme	7,303 (2025)
PMTCT ART coverage among pregnant women with HIV	Treatment cascade	percent	31	2010–2025	UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset	50.0% (2025)
People living with HIV in care screened for TB	Treatment cascade	count	1	2017	Global Fund Data Service	10,539 (2017)
People living with HIV on ART who started TB preventive therapy	Treatment cascade	count	6	2017–2025	Global Fund Data Service	226 (2025)
People newly diagnosed at a health facility	Treatment cascade	count	3	2018–2020	PEPFAR testing by modality	42 (2020)
People newly diagnosed through community outreach	Treatment cascade	count	5	2018–2022	PEPFAR testing by modality	86 (2022)
People newly enrolled on ART during the year	Treatment cascade	count	12	2014–2023	PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme	449 (2023)
People on ART at HHS/CDC-funded partners (MER TX_CURR)	Treatment cascade	count	3	2018–2020	PEPFAR results by funding agency	4,325 (2020)
People on ART on a dolutegravir-based regimen	Treatment cascade	percent	6	2020–2025	PAHO Interactive HIV Data Dashboard	By population group, sex or age only, to 2025
People tested for HIV in the last 12 months who received the result (household survey)	Treatment cascade	percent	24	2005–2009	Demographic and Health Surveys	By population group, sex or age only, to 2009
Pregnant women tested for HIV in antenatal care	Treatment cascade	percent	14	2011–2024	UNAIDS AIDSinfo	98.0% (2024)
Pregnant women with HIV who received ARVs for PMTCT	Treatment cascade	count	36	2010–2025	Global Fund Data Service, UNAIDS AIDSinfo, WHO Global Health Observatory	172 (2025)
TB patients recorded as HIV-positive	Treatment cascade	count	15	2015–2024	WHO Global Tuberculosis Programme	56 (2024)
TB patients with an HIV test result recorded	Treatment cascade	count	17	2015–2024	Global Fund Data Service, WHO Global Tuberculosis Programme	333 (2024)
AIDS-related deaths	Epidemic estimates	count	681	2000–2025	UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory	200 (2025)
Deaths from TB among people living with HIV	Epidemic estimates	count	50	2000–2024	UNAIDS AIDSinfo, WHO Global Tuberculosis Programme	23 (2024)
HIV prevalence among a key population	Epidemic estimates	percent	4	2024	UNAIDS AIDSinfo	By population group, sex or age only, to 2024
HIV prevalence, ages 15-49	Epidemic estimates	percent	50	2000–2024	UNAIDS AIDSinfo, World Bank Open Data	1.6% (2024)
Incident TB cases among people living with HIV	Epidemic estimates	count	50	2000–2024	UNAIDS AIDSinfo, WHO Global Tuberculosis Programme	93 (2024)
New HIV infections	Epidemic estimates	count	585	2000–2025	UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory	500 (2025)
People living with HIV	Epidemic estimates	count	681	2000–2025	UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory	11,000 (2025)
Condom use at last higher-risk sex (household survey)	Prevention and outreach	percent	24	2005–2009	Demographic and Health Surveys	By population group, sex or age only, to 2009
Key-population people reached by outreach (count over the period)	Prevention and outreach	count	25	2017–2025	Global Fund Data Service	By population group, sex or age only, to 2025
Male condoms distributed in a year	Prevention and outreach	count	3	2022–2024	UNAIDS AIDSinfo	6,169,200 (2024)
People receiving PrEP	Prevention and outreach	count	6	2021–2025	Global Fund Data Service, UNAIDS AIDSinfo	5,200 (2024)
People with comprehensive correct knowledge of HIV (household survey)	Prevention and outreach	percent	28	2005–2009	Demographic and Health Surveys	By population group, sex or age only, to 2009
Estimated pregnant women with HIV needing ARVs for PMTCT	Population denominators	count	31	2010–2025	UNAIDS AIDSinfo, WHO Global Health Observatory	500 (2025)
Estimated size of a key population	Population denominators	count	2	2024	UNAIDS AIDSinfo	By population group, sex or age only, to 2024
Total population	Population denominators	count	26	2000–2025	World Bank Open Data	835,986 (2025)
Share of HIV-exposed infants who acquire HIV	—	percent	31	2010–2025	UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset	20.2% (2025)

Every row shown on the Guyana page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.